Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. - Wikidata - awgldk - TriplyDB

Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

http://www.wikidata.org/entity/Q36813115

about

Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis Hepatic circadian-clock system altered by insulin resistance, diabetes and insulin sensitizer in mice PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease Metabolism in HD: still a relevant mechanism?Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria Targets for future clinical trials in Huntington's disease: what's in the pipeline?Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.Nuclear receptors in neurodegenerative diseases.PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria.HMG-CoA Reductase Inhibitors Bind to PPARα to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice.PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.Neuroprotective Potential of Peroxisome Proliferator Activated Receptor- α Agonist in Cognitive Impairment in Parkinson's Disease: Behavioral, Biochemical, and PBPK Profile.Cell proliferation and neuroblast differentiation in the dentate gyrus of high-fat diet-fed mice are increased after rosiglitazone treatment.Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.Neuroprotective effects of psychotropic drugs in Huntington's disease Potential therapeutic targets in polyglutamine-mediated diseases.Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition.Synaptic signalling and its interface with neuropathologies: snapshots from the past, present and future.14,15-epoxyeicosatrienoic acid promotes production of brain derived neurotrophic factor from astrocytes and exerts neuroprotective effects during ischaemic injury.PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.Emerging Roles of Sirtuins in Ischemic Stroke.Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.Neurodegeneration Alters Metabolic Profile and Sirt 1 Signaling in High-Fat-Induced Obese Mice.Biochemical characterization of sirtuin 6 in the brain and its involvement in oxidative stress response.Localization of PPAR isotypes in the adult mouse and human brain.Mass Spectrometry Analysis of Wild-Type and Knock-in Q140/Q140 Huntington's Disease Mouse Brains Reveals Changes in Glycerophospholipids Including Alterations in Phosphatidic Acid and Lyso-Phosphatidic Acid.Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.Rosiglitazone as a Modulator of TLR4 and TLR3 Signaling Pathways in Rat Primary Neurons and Astrocytes.Towards an Understanding of Energy Impairment in Huntington's Disease Brain.Therapy development in Huntington disease: From current strategies to emerging opportunities.Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.

P2860

Q26795417-10DE75B7-630E-4DDF-B4A3-5FCA131CCAA0 Q27026549-4283C7B9-1549-4192-99AA-8712F1B6776B Q27311473-767F06D1-35FA-4E8C-8C68-18CC94ACB3AD Q28069549-35E835DC-F2B0-41C0-96E7-8CB702DD0467 Q28394301-06CE3A77-6B62-43FE-ABE7-40AE53A68B6D Q33721892-B387BF85-6CFE-4F84-8240-53F53C823344 Q34435001-3B776A92-3FB4-4A92-9398-E08BD6459A00 Q34440282-F0C0DBD1-8EF3-474F-8B18-006FB981BC23 Q34580020-9A7DF4A0-11B6-458A-B037-F2D52A265B44 Q35113069-DB90A38B-D38E-47DF-8DB0-2619FEBA1453 Q35920862-81790BC4-B8D3-4413-BC4D-725560095F66 Q36575566-1A752BF7-F25E-4102-8FEC-5596C3345003 Q37105051-ABE8A354-5C2E-4C21-950E-71A4851E6047 Q37368003-1A2599F4-B27D-4CAF-8806-3C12D4B10F9C Q37622376-DD92BE88-5C7A-48D4-82E8-6FD3CF41EE6B Q37681097-4438C40A-E813-49E8-B151-BB218970476A Q37686240-28C8EA04-BC77-4874-A533-334A10A25B46 Q38163877-00C25738-4610-49FF-9DBD-4E05072AA54E Q38246221-8A944621-D7EA-4758-BD95-2303BE371DAE Q38663090-9C87B7FD-3E35-4B5B-835D-625BFB086D44 Q38731136-948F363B-0AE4-4EC5-98E1-95EC3425187A Q38802640-A01CE7EE-AD19-4C1B-9AAC-AB2599A1A446 Q38822739-3C7A0C64-394A-4E16-AAB2-0CF03D14FE1F Q39145017-2F6CE30C-BAEB-48BE-844A-8CB879A98E25 Q39401700-03B6850C-9B26-4B06-8560-5EE04CF5D574 Q40075003-66443019-CC1E-45CC-9443-D1F7A5B8FE7B Q42108641-BD31F69F-CEAD-4490-A7AC-D80145203338 Q42182310-3D4BE4E7-957A-47A1-A2E2-E6EA55BAC17B Q42735293-23165790-080B-48AD-9357-A2A080F21BE2 Q45290192-8671FCF9-FD4B-4D79-A197-08D279635760 Q45297835-3F075BDF-1CB4-469F-AFF3-B9A3DF50CCB4 Q47232222-74420DC8-AC52-49A5-AA49-0E16FA1DF801 Q47442924-F85F13EA-8462-43CE-9493-7ED5B2002553 Q53716390-112A7886-6C7D-4048-A29E-BEC2412DA636 Q54965657-154D9A67-6027-419D-8CB1-F2B24356135F

P2860

Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

http://www.wikidata.org/entity/Q36813115

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Neuroprotective effects of PPA ...... model of Huntington's disease.

@ast

Neuroprotective effects of PPA ...... model of Huntington's disease.

@en

type

label

Neuroprotective effects of PPA ...... model of Huntington's disease.

@ast

Neuroprotective effects of PPA ...... model of Huntington's disease.

@en

prefLabel

Neuroprotective effects of PPA ...... model of Huntington's disease.

@ast

Neuroprotective effects of PPA ...... model of Huntington's disease.

@en

P1433

Q36813115-4AC19BFA-1B89-44BA-9C24-843A468263F9

P1476

Q36813115-A3F7615A-1222-4D80-A2D1-9562C5351B07

P2093

Q36813115-03DB2E43-723F-4CF7-B548-3E31D246E5C1

Q36813115-25C97DC6-04FB-47D5-8C94-2C106DFC8200

Q36813115-415B0D2E-74C8-4F9E-96D0-5C10B1891687

Q36813115-A82216E3-59BE-407F-A8BA-A71F83C3ABE2

Q36813115-B349F498-C6ED-40EE-A55C-E8B5E49D6925

Q36813115-DB324102-B663-4535-9128-D7EF1176A02C

Q36813115-F546BABF-A9A0-4075-BD28-9B4DE4563159

P2860

Q36813115-0255A371-72C8-4673-85E4-187E3BE8B7CE

Q36813115-0358024E-2139-49C3-9761-DD33779DB0B0

Q36813115-0496BDB9-04C7-4864-816D-C2206311CAED

Q36813115-04F50F4F-D9DE-4E39-A8DE-66D6ADAA842E

Q36813115-058179FE-F2A3-4B3B-8357-C35D5F6E97F2

Q36813115-08E17559-3F1B-4FBA-A725-45CE729FBD0F

Q36813115-11304AEF-C9E5-4C78-9675-F92410292155

Q36813115-14A83FA8-966B-4EF0-9EC9-F681C59C2DC2

Q36813115-18E895C9-29A7-49EC-8D38-016810B7721A

Q36813115-1EEF784A-7635-4BB4-BD0F-A9A750BF10DE

P304

Q36813115-D6F4A70A-1FA3-43D9-B39C-C780D876C07E

P31

Q36813115-EB7538B4-619F-4863-8224-5147B13D76D9

P356

Q36813115-311095B4-5F75-40EE-BDF5-0E3A8778DEE4

P407

Q36813115-2C3E02FA-4536-4C6E-94D8-4CB392EBFDFC

P433

Q36813115-3071358D-454A-4F69-AF99-2B46E7C95FB9

P478

Q36813115-97872C75-738F-4B46-A885-E8C4D583554D

P50

Q36813115-C7E27D05-0E45-4792-8367-B4FEC9FD16E1

P577

Q36813115-F3CBF2E6-FD80-4B3B-A42B-7619E91B20BC

P698

Q36813115-C93520E1-05D2-4D03-9FAF-E5A97156F596

P921

Q36813115-97AF1422-76DC-4F59-B830-84A96E1BD6DD

P932

Q36813115-FCCAE7A8-B240-47AD-94BB-0E468C58078A

P356

P1433

Journal of Neurochemistry

P1476

Neuroprotective effects of PPA ...... model of Huntington's disease.

@en

P2093

Gay Rudow

http://www.w3.org/2001/XMLSchema#string

Jennifer Albertz

http://www.w3.org/2001/XMLSchema#string

Jing Jin

http://www.w3.org/2001/XMLSchema#string

Juan C Troncoso

http://www.w3.org/2001/XMLSchema#string

Qi Peng

http://www.w3.org/2001/XMLSchema#string

Wenzhen Duan

http://www.w3.org/2001/XMLSchema#string

Zhihong Guo

http://www.w3.org/2001/XMLSchema#string

P2860

The hypocretin/orexin system

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease

SIRT6 in DNA repair, metabolism and ageing

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

PGC-1alpha: a key regulator of energy metabolism

The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha

Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice

Mitochondrial matters of the brain: the role in Huntington's disease.

Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression

Huntington's disease: from molecular pathogenesis to clinical treatment.

P304

410-419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JNC.12190

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Christopher A Ross

P577

2013-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23373812

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

3642978

http://www.w3.org/2001/XMLSchema#string